• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Corrigendum to 'ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2' [Canc. Lett. 427 (2018) 9-17].

作者信息

Luo Qingyu, Wu Xiaowei, Zhang Yiping, Shu Tong, Ding Fang, Chen Hongyan, Zhao Pengfei, Chang Wan, Zhu Xiaolin, Liu Zhihua

机构信息

State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Department of Gynecological Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

出版信息

Cancer Lett. 2021 Feb 1;498:243. doi: 10.1016/j.canlet.2020.10.027. Epub 2020 Oct 22.

DOI:10.1016/j.canlet.2020.10.027
PMID:33342532
Abstract
摘要

相似文献

1
Corrigendum to 'ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2' [Canc. Lett. 427 (2018) 9-17].
Cancer Lett. 2021 Feb 1;498:243. doi: 10.1016/j.canlet.2020.10.027. Epub 2020 Oct 22.
2
ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2.ARID1A 缺失通过转录激活 MRP2 导致卵巢癌多药耐药。
Cancer Lett. 2018 Jul 28;427:9-17. doi: 10.1016/j.canlet.2018.04.013. Epub 2018 Apr 13.
3
Corrigendum to "Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer" [Canc. Lett. 459 (2019 Sep 10) 122-134].
Cancer Lett. 2022 Jul 28;539:215695. doi: 10.1016/j.canlet.2022.215695. Epub 2022 Apr 29.
4
Corrigendum to "DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer" [Canc. Lett. 501 224-233].《“DIO3，甲状腺激素失活酶，促进高级别浆液性卵巢癌的肿瘤发生和代谢重编程”的勘误》[《癌症通讯》501 224 - 233]
Cancer Lett. 2023 Jun 1;563:216196. doi: 10.1016/j.canlet.2023.216196. Epub 2023 Apr 25.
5
Corrigendum to "NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma" [Canc. Lett. 476 (2020) 48-56].《NRF2/SHH信号级联促进肝细胞癌肿瘤起始细胞谱系及耐药性》[《癌症快报》476卷（2020年）第48 - 56页]的勘误
Cancer Lett. 2021 Feb 28;499:2. doi: 10.1016/j.canlet.2020.06.007. Epub 2020 Jun 17.
6
Corrigendum to "UBE2T promotes radiation resistance in non-small cell lung cancer via inducing epithelial-mesenchymal transition and the ubiquitination-mediated FOXO1 degradation" [Canc. Lett. 494 (2020) 121-131].对“UBE2T通过诱导上皮-间质转化和泛素化介导的FOXO1降解促进非小细胞肺癌的辐射抗性”的勘误 [《癌症快报》494 (2020) 121-131]。
Cancer Lett. 2022 Sep 1;543:215792. doi: 10.1016/j.canlet.2022.215792. Epub 2022 Jun 17.
7
Corrigendum to "FAT1 prevents epithelial mesenchymal transition (EMT) via MAPK/ERK signaling pathway in esophageal squamous cell cancer" [Canc. Lett. 397 (2017) 83-93].《“FAT1通过MAPK/ERK信号通路抑制食管鳞状细胞癌上皮-间质转化（EMT）”的勘误》[《癌症通讯》397（2017）83 - 93]
Cancer Lett. 2020 Dec 1;494:1-2. doi: 10.1016/j.canlet.2020.07.038. Epub 2020 Aug 17.
8
Corrigendum to "Polypyrimidine tract binding protein 1 promotes lymphatic metastasis and proliferation of bladder cancer via alternative splicing of MEIS2 and PKM." [Canc. Lett. 449 (2019) 31-44].《“多嘧啶序列结合蛋白1通过MEIS2和PKM的可变剪接促进膀胱癌的淋巴转移和增殖”的勘误》[《癌症通讯》449（2019）31 - 44]
Cancer Lett. 2021 Mar 1;500:292-293. doi: 10.1016/j.canlet.2020.12.027. Epub 2020 Dec 31.
9
Corrigendum to "Preclinical anti-cancer activity and multiple mechanisms of action of a cationic silver complex bearing N-heterocyclic carbene ligands" [Canc. Lett. 403 (2017) 98-107].
Cancer Lett. 2018 Sep 1;431:247. doi: 10.1016/j.canlet.2018.06.022. Epub 2018 Jun 19.
10
Corrigendum to "Induction of hypoxia-inducible factor-1alpha overexpression by cobalt chloride enhances cellular resistance to photodynamic therapy" [Canc. Lett 244 (2006) 182-189].
Cancer Lett. 2021 Feb 1;498:244. doi: 10.1016/j.canlet.2020.10.026. Epub 2020 Oct 24.